{"id":3273,"date":"2023-05-07T22:02:57","date_gmt":"2023-05-07T22:02:57","guid":{"rendered":"https:\/\/healthnews.zone\/?p=3273"},"modified":"2023-05-07T22:02:58","modified_gmt":"2023-05-07T22:02:58","slug":"alzheimers-drug-donanemab-what-promising-trial-means-for-treatments","status":"publish","type":"post","link":"https:\/\/healthnews.zone\/?p=3273","title":{"rendered":"Alzheimer\u2019s Drug Donanemab: What Promising Trial Means for Treatments"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over its potential side effects.<\/h3>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img decoding=\"async\" src=\"data:image\/svg+xml,%3Csvg%20xmlns='http:\/\/www.w3.org\/2000\/svg'%20viewBox='0%200%20370%20247'%3E%3C\/svg%3E\" data-lazy-src=\"https:\/\/healthnews.zone\/wp-content\/uploads\/2023\/05\/image-54.png\" alt=\"\" class=\"zeen-lazy-load-base zeen-lazy-load wp-image-3274\"\/><noscript><img decoding=\"async\" width=\"767\" height=\"656\" src=\"https:\/\/healthnews.zone\/wp-content\/uploads\/2023\/05\/image-54.png\" alt=\"\" class=\"wp-image-3274\" srcset=\"https:\/\/healthnews.zone\/wp-content\/uploads\/2023\/05\/image-54.png 767w, https:\/\/healthnews.zone\/wp-content\/uploads\/2023\/05\/image-54-300x257.png 300w, https:\/\/healthnews.zone\/wp-content\/uploads\/2023\/05\/image-54-293x251.png 293w, https:\/\/healthnews.zone\/wp-content\/uploads\/2023\/05\/image-54-390x334.png 390w\" sizes=\"(max-width: 767px) 100vw, 767px\" \/><\/noscript><figcaption class=\"wp-element-caption\"><em>An MRI scan shows shrinkage around the front and sides of the brain of a person with early-onset Alzheimer&#8217;s disease.Credit: Zephyr\/SPL<\/em><\/figcaption><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">For the second time, an experimental drug has been shown to reduce the cognitive decline associated with Alzheimer\u2019s disease. On 3 May, pharmaceutical company Eli Lilly announced in a press release that its monoclonal antibody donanemab slowed mental decline by 35% for some participants in a 1,736-person trial \u2014 a rate comparable to that for competitor drug lecanemab. But researchers warn that until the full results are published, questions remain as to the drug\u2019s clinical usefulness, as well as whether the modest benefit outweighs the risk of harmful side effects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Read more: <a href=\"https:\/\/www.nature.com\/articles\/d41586-023-01537-5\">https:\/\/www.nature.com\/articles\/d41586-023-01537-5<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over its potential side effects. For the second time, an experimental drug has been shown to reduce the cognitive decline associated with Alzheimer\u2019s disease. On 3 May, pharmaceutical company Eli Lilly announced in a press release that its monoclonal antibody donanemab slowed mental decline by 35% for some participants in a 1,736-person trial \u2014 a rate comparable to that for competitor drug lecanemab. But [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-3273","post","type-post","status-publish","format-standard","hentry","category-conditions"],"_links":{"self":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/3273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3273"}],"version-history":[{"count":1,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/3273\/revisions"}],"predecessor-version":[{"id":3275,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/3273\/revisions\/3275"}],"wp:attachment":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}